Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Institute of Chinese Materia Medica of China Academy of Chinese Medical Sciences | 2 |
| 2 | Anhui Medical University | 1 |
| 3 | CapitalBio Corp | 1 |
| 4 | Excrx Singapore Pte Ltd | 1 |
| 5 | Kunming Institute of Botany | 1 |
| 6 | Lion Corp | 1 |
| 7 | South China Institute of Botany | 1 |
| 8 | University of Pennsylvania | 1 |
| 9 | Zhenping Power Supply Co of State Grid Henan Electric Power Co Ltd | 1 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 112 |
| 2 | A61P | Therapeutic activity (drug indications) | 53 |
| 3 | G01N | Investigating / analysing materials | 51 |
| 4 | Y02A | Climate change adaptation | 41 |
| 5 | A23L | Foods and beverages (general) | 25 |
| 6 | A61Q | Cosmetics, personal care | 20 |
| 7 | A23V | Foods, foodstuffs - indexing scheme | 14 |
| 8 | A01G | 10 | |
| 9 | A01N | Preservation of bodies; biocides; pest repellents | 10 |
| 10 | C07D | Heterocyclic compounds | 10 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Endophytic fungi capable of improving content of isofraxidin in Radix Acanthopanacis Semticosi through fermenting Radix Acanthopanacis Semticosi | 2012 | HEILONGJIANG UNIVERSITY | 6 |
| Technology for synchronously extracting isofraxidin and flavonoids compounds from sarcandra glabra and applications thereof | 2010 | Sanming Huajian Bioengineering Co.Ltd | 5 |
| One kind prepares isofraxidin method from Chinese medicinal material of sarcandra glaber | 2017 | GUANGDONG PROV. CHINESE MEDICINE HOSPITAL | 2 |
| Method for extracting isofraxidin | 2011 | NANJING ZELANG AGRICULTURAL DEVELOPMENT CO., LTD. | 2 |
| Isofraxidin crystalline compound and glabrous sarcandra herb dispersible tablets and dropping pills containing isofraxidin crystalline compound | 2012 | ZHEJIANG WECOME MEDICINE LNDUSTRY CO., LTD. | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Kaishun Bi | Shenyang Pharmaceutical University | 6 |
| 2 | Haitao Lv | Heilongjiang University of Chinese Medicine | 5 |
| 3 | Hui Sun | Shenyang Pharmaceutical University | 5 |
| 4 | Xijun Wang | Heilongjiang University of Chinese Medicine | 5 |
| 5 | Yanmei Zhang | Heilongjiang University of Chinese Medicine | 5 |
| 6 | Hongxin Cao | China Academy of Chinese Medical Sciences | 4 |
| 7 | Taisuke Yamazaki | Kohno Clinical Medicine Research Institute | 4 |
| 8 | Weifeng Li | Xi'an Jiaotong University | 4 |
| 9 | Takayoshi Tokiwa | Kohno Clinical Medicine Research Institute | 3 |
| 10 | Ting Fan | Xi'an Jiaotong University | 3 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Constituents and pharmacological effects of Eucommia and Siberian ginseng. | 2001 | 261 | Natural product bioactivities and synthesis |
| Interaction of isofraxidin with human serum albumin | 2003 | 128 | Drug Transport and Resistance Mechanisms |
| Isofraxidin exhibited anti-inflammatory effects in vivo and inhibited TNF-α production in LPS-induced mouse peritoneal macrophages in vitro via the MAPK pathway | 2012 | 92 | Genomics, phytochemicals, and oxidative stress |
| Isofraxidin, a Coumarin Component from Acanthopanax senticosus, Inhibits Matrix Metalloproteinase-7 Expression and Cell Invasion of Human Hepatoma Cells | 2010 | 86 | Natural product bioactivities and synthesis |
| Isofraxidin, a potent reactive oxygen species (ROS) scavenger, protects human leukemia cells from radiation-induced apoptosis via ROS/mitochondria pathway in p53-independent manner | 2014 | 80 | Genomics, phytochemicals, and oxidative stress |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and structure of Isofraxidin?
Which organizations hold patents for Isofraxidin applications?
What are the primary research topics covered by publications on Isofraxidin?
Who are the most prolific authors publishing on Isofraxidin?
What is the patent classification landscape for Isofraxidin?